Chronic active Epstein-Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation

T. Taketani; A. Kikuchi; J. Inatomi; R. Hanada; H. Kawaguchi; K. Ida; T. Oh-Ishi; T. Arai; H. Kishimoto; K. Yamamoto

doi:10.1038/sj/bmt/1703392

Chronic active Epstein-Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation

T. Taketani
, A. Kikuchi
, J. Inatomi
, R. Hanada
, H. Kawaguchi
, K. Ida
, T. Oh-Ishi
, T. Arai
, H. Kishimoto
, K. Yamamoto

Saitama Children's Medical Center

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

We report a pediatric case of CAEBV and T cell-based Hodgkin's-like disease successfully treated with allo PBSCT from an HLA-matched sibling. The diagnosis of CAEBV was made from clinical signs and the presence of the EBV genome in PBMC and tumor cells. Conditioning with busulfan (BU) + etoposide (VP16) + cyclophosphamide (CY) was effective and well tolerated. EBV was totally eradicated by 3 months after allo PBSCT. Although she suffered from chronic GVHD of the liver, she has been well and free of disease for 47 months since PBSCT. We suggest allo PBSCT for CAEBV as a potent therapeutic strategy for eradication of the EBV genome and allowing immunological reconstitution.

Original language	English
Pages (from-to)	531-533
Number of pages	3
Journal	Bone Marrow Transplantation
Volume	29
Issue number	6
DOIs	https://doi.org/10.1038/sj/bmt/1703392
State	Published - 2002
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Allo PBSCT
CAEBV
EBV in situ hybridization
Malignant lymphoma

Access to Document

10.1038/sj/bmt/1703392

Cite this

@article{3f39a4cb232d4d188f1b3ffdd224cc5e,

title = "Chronic active Epstein-Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation",

abstract = "We report a pediatric case of CAEBV and T cell-based Hodgkin's-like disease successfully treated with allo PBSCT from an HLA-matched sibling. The diagnosis of CAEBV was made from clinical signs and the presence of the EBV genome in PBMC and tumor cells. Conditioning with busulfan (BU) + etoposide (VP16) + cyclophosphamide (CY) was effective and well tolerated. EBV was totally eradicated by 3 months after allo PBSCT. Although she suffered from chronic GVHD of the liver, she has been well and free of disease for 47 months since PBSCT. We suggest allo PBSCT for CAEBV as a potent therapeutic strategy for eradication of the EBV genome and allowing immunological reconstitution.",

keywords = "Allo PBSCT, CAEBV, EBV in situ hybridization, Malignant lymphoma",

author = "T. Taketani and A. Kikuchi and J. Inatomi and R. Hanada and H. Kawaguchi and K. Ida and T. Oh-Ishi and T. Arai and H. Kishimoto and K. Yamamoto",

year = "2002",

doi = "10.1038/sj/bmt/1703392",

language = "英語",

volume = "29",

pages = "531--533",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Springer Nature",

number = "6",

}

TY - JOUR

T1 - Chronic active Epstein-Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation

AU - Taketani, T.

AU - Kikuchi, A.

AU - Inatomi, J.

AU - Hanada, R.

AU - Kawaguchi, H.

AU - Ida, K.

AU - Oh-Ishi, T.

AU - Arai, T.

AU - Kishimoto, H.

AU - Yamamoto, K.

PY - 2002

Y1 - 2002

N2 - We report a pediatric case of CAEBV and T cell-based Hodgkin's-like disease successfully treated with allo PBSCT from an HLA-matched sibling. The diagnosis of CAEBV was made from clinical signs and the presence of the EBV genome in PBMC and tumor cells. Conditioning with busulfan (BU) + etoposide (VP16) + cyclophosphamide (CY) was effective and well tolerated. EBV was totally eradicated by 3 months after allo PBSCT. Although she suffered from chronic GVHD of the liver, she has been well and free of disease for 47 months since PBSCT. We suggest allo PBSCT for CAEBV as a potent therapeutic strategy for eradication of the EBV genome and allowing immunological reconstitution.

AB - We report a pediatric case of CAEBV and T cell-based Hodgkin's-like disease successfully treated with allo PBSCT from an HLA-matched sibling. The diagnosis of CAEBV was made from clinical signs and the presence of the EBV genome in PBMC and tumor cells. Conditioning with busulfan (BU) + etoposide (VP16) + cyclophosphamide (CY) was effective and well tolerated. EBV was totally eradicated by 3 months after allo PBSCT. Although she suffered from chronic GVHD of the liver, she has been well and free of disease for 47 months since PBSCT. We suggest allo PBSCT for CAEBV as a potent therapeutic strategy for eradication of the EBV genome and allowing immunological reconstitution.

KW - Allo PBSCT

KW - CAEBV

KW - EBV in situ hybridization

KW - Malignant lymphoma

UR - https://www.scopus.com/pages/publications/0036240613

U2 - 10.1038/sj/bmt/1703392

DO - 10.1038/sj/bmt/1703392

M3 - 記事

C2 - 11960276

AN - SCOPUS:0036240613

SN - 0268-3369

VL - 29

SP - 531

EP - 533

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 6

ER -

Chronic active Epstein-Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this